Study Details

Back
Study ID 9766-CL-0104
Study Title A phase III, double-blind, randomized study to evaluate safety and efficacy of BAL8557 versus voriconazole for primary treatment of invasive fungal disease caused by Aspergillus species or other filamentous fungi
Clinicaltrials.gov Identifier NCT00412893
Compound Name BAL8557 / isavuconazonium sulfate
Medical Indication or Disease Invasive fungal infection
Study Sponsor Astellas Pharma Global Development, Inc.
Collaborator Basilea Pharmaceutica International, Ltd.
Study Start Date 07-Mar-2007
Study Completion Date 28-Mar-2013
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
English

QUICK SEARCH

USEFUL LINKS